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CASE REPORT
SEROCONVERTION TO HEPATITIS B VACCINE AFTER WEIGHT REDUCTION
IN OBESE NON-RESPONDER
Maria Isabel Saraiva DINELLI & Maria Isabel de MORAES-PINTO
SUMMARY
Decreased responses to hepatitis B vaccine have been associated with some host conditions including obesity. Susceptible
non-responders to a primary three-dose vaccine series should be revaccinated. Those who maintain a non-responder condition
after revaccination with three vaccine doses are unlikely to develop protection using more doses. This is a description of an obese
woman who received six doses of hepatitis B vaccine and persisted as a non-responder. She was submitted to a vertical banded
gastroplasty Roux-en-Y gastric bypass Capellas’s technique. After weight reduction, she received three additional doses of vaccine
and seroconverted. Further studies should help clarify the need to evaluate antibody levels and eventually revaccinate the increasing
population of individuals who undergo weight reduction.
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CASE REPORT
Hepatitis B vaccine is highly immunogenic. Three vaccine doses induce
protective antibodies (anti-HBs ≥ 10 mIU/mL) in over 90% of healthy
adults under 40 years of age3,10,12. Response to vaccination in children and
adolescents occurs in more than 95% of vaccinees10. Decreased vaccine
responses have been associated with some host conditions, such as older
age, male gender, smoking, genetic factors, chronic disease, and obesity2-
3,8,10-12,14,16-19
. Also, poor antibody response in obese persons may be linked
to inadvertent injection of vaccine into adipose tissue16.
Individuals who do not attain anti-HBs ≥ 10 mIU/mL after a primary
vaccine series should be revaccinated. Those who maintain a non-
responder condition after revaccination with three vaccine doses are
unlikely to develop protection using further doses3,10. A variable
seroconversion rate was achieved after revaccination in different
studies3-5,20-21. Higher body mass index was associated to lower
geometric mean titres (GMTs) after a revaccination series4.
This is a description of an obese 31-year-old woman, previously
susceptible to hepatitis B infection (with negative anti-HBs and anti-
HBc antibodies). Her body mass index, weight (kg) / height (m)2, was
37.3% during the first 3-dose vaccination schedule (0, 1 and 8 months)
and 35.7% in the second 3-dose schedule (0, 1, 6 months). Hepatitis B
recombinant DNA vaccines were from SmithKlein Beecham
Biologicals (Rixensart, Belgium), but for the sixth dose, which was
from Merck Sharp Dohme (West Point, USA). All doses were injected
intramuscularly into the deltoid muscle. After six vaccine doses, the
patient was a non-responder, with negative anti-HBs, anti-HBc and
HBs-Ag as assessed by radioimmunoassay (Abbott, USA). Nine months
after the last vaccine dose, the patient was submitted to a laparoscopic
vertical banded gastroplasty Roux-en-Y gastric bypass, Capellas’s
technique. She lost weight, and her body mass index dropped to 20.5%.
At that time point, she was re-tested for anti-HBs antibodies by
electrochemiluminescence assay (Roche) and was not reagent. Although
there were no recommendations for revaccination among healthy adults
who did not seroconvert after two vaccine series, the patient received a
third series of vaccines against hepatitis B from Merck Sharp Dohme
(West Point, USA) in a 0, 1, 6 month schedule again in the deltoid
muscle. Three months after the third dose, anti-HBs antibody
concentration increased to 39 mUI/mL as assessed by
electrochemiluminescence (Roche).
Obesity has been associated with many health conditions, such as
coronary heart disease, hypertension, diabetes mellitus and
dyslipidemia. Obese individuals can also have dysfunction in the
immune system7,9,15. Previous studies have shown an association
between obesity and poor antibody response to hepatitis B vaccine2-
3,12,14,16,18
. Different studies have shown that lymphocytes from obese
individuals have altered number and also a reduced lymphoproliferative
response to “in vitro” stimuli7,9,15. TANAKA et al. noted that obese
subjects had diminished number of CD3+, CD4+ and CD8+ T cells and
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a reduced blastogenic T cell response to mitogens. Interestingly, weight
reduction led to an increase in T cell responses and in the number of
CD4+ and NK cells15.
On the other hand, it is known that individuals who do not present
a serologic response to hepatitis B vaccine can develop a specific
cellular immune response6. Also, non-responder individuals to the
current licensed hepatitis B vaccine might benefit from new candidate
vaccines with different antigens and adjuvants5,13,22.
As our patient responded to the extra three-dose vaccine scheme
after weight reduction, factors such as an altered immune response due
to obesity or inadverted injection of previous vaccine doses into adipose
tissue might have been responsible for the lack of seroconvertion after
two vaccine series. Further studies should help clarify the need to evaluate
antibody levels and eventually revaccinate the increasing population of
individuals who undergo surgery for weight reduction.
RESUMO
Soroconversão à vacina contra hepatite B após redução de peso
em obeso não respondedor
A diminuição da resposta à vacinação contra hepatite B já foi
relacionada a algumas condições clínicas, inclusive à obesidade.
Indivíduos que não responderam à série de três doses devem ser
revacinados. Caso continuem não-respondedores após duas séries de
vacina, não há indicação de doses adicionais. Esta é a descrição de
mulher obesa que não havia soroconvertido após ter recebido seis doses
de vacina contra hepatite B. Ela foi submetida à gastroplastia em Y de
Roux, pela técnica de Capella. Após a redução de peso, a paciente
recebeu mais três doses de vacina contra hepatite B e soroconverteu.
Novos estudos poderão indicar a necessidade de avaliação de níveis de
anticorpos contra antígenos vacinais e eventualmente revacinar esta
população cada vez maior de pacientes que se submetem à cirurgia
para redução de peso.
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